A5103228335- Diabetes Treatment and Management
- Chronic Kidney Disease and Diabetes
- Renal Diseases and Glomerulopathies
- Dialysis and Renal Disease Management
- Blood Pressure and Hypertension Studies
- Pancreatic function and diabetes
- Diabetes Management and Research
- Diet and metabolism studies
- Vasculitis and related conditions
- Autoimmune Bullous Skin Diseases
- Erythropoietin and Anemia Treatment
- Organ Donation and Transplantation
- Statistical Methods in Clinical Trials
- Diabetes and associated disorders
- COVID-19 Clinical Research Studies
- Sodium Intake and Health
- Hormonal Regulation and Hypertension
- Machine Learning in Healthcare
- Birth, Development, and Health
- Medication Adherence and Compliance
- Influenza Virus Research Studies
- Renal and Vascular Pathologies
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Peptidase Inhibition and Analysis
- Pancreatic and Hepatic Oncology Research
Innsbruck Medical University
2015-2024
Universität Innsbruck
2016-2024
Klinikum St. Georg
2023
Mosaiques Diagnostics and Therapeutics (Germany)
2023
Toronto General Hospital
2023
University of Toronto
2023
Hospital Universitario Fundación Jiménez Díaz
2023
Universidad Autónoma de Madrid
2023
Umeå University
2023
Skaraborg Hospital
2023
The aim of this study was to investigate 28-day mortality after COVID-19 diagnosis in the European kidney replacement therapy population. In addition, we determined role patient characteristics, treatment factors, and country on risk with use ERA-EDTA Registry data patients receiving Europe from February 1, 2020, April 30, 2020. Additional all a were collected 7 countries encompassing 4298 patients. COVID-19–attributable calculated using propensity score–matched historic control 28 days...
Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and need for supplemental was rare. However, widespread ESAs, it recognized that necessary optimize hemoglobin response allow reduction ESA dose economic reasons recent concerns about safety. Iron supplementation also found be more efficacious via intravenous compared oral administration, use has escalated years. The safety...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin slows progression of kidney function decline in type diabetes. aim this study was to assess the effect SGLT2 on biomarkers for diabetic disease (DKD).A mechanism action (MoA) network model constructed based an vitro transcriptomics experiment human proximal tubular cells and molecular features linked inhibitors from scientific literature. This mapped onto established DKD that describes processes associated with DKD....
ObjectivesTo assess the association of public interest in coronavirus infections with actual number infected cases for selected countries across globe.MethodsWe performed a Google TrendsTM search “Coronavirus” and compared Relative Search Volumes (RSV) indices to reported COVID-19 by European Center Disease Control (ECDC) using time-lag correlation analysis.ResultsWorldwide Coronavirus reached its first peak end January when numbers newly patients started increase exponentially China. The...
Finerenone reduced the risk of kidney and cardiovascular events in people with chronic disease (CKD) type 2 diabetes FIDELIO-DKD FIGARO-DKD phase 3 studies. Effects finerenone on outcomes patients taking sodium-glucose cotransporter inhibitors (SGLT2is) were evaluated a prespecified pooled analysis these studies.Patients urine albumin-to-creatinine ratio (UACR) ≥30 to ≤5,000 mg/g estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m2 randomly assigned or placebo; SGLT2is permitted at...
In chronic kidney disease (CKD), the decline in glomerular filtration rate is associated with increased morbidity and mortality thus poses a major challenge for healthcare systems. While contribution of tissue-derived miRNAs mRNAs to CKD progression has been extensively studied, little known about role urinary exosomes their association CKD. Exosomes are small, membrane-derived endocytic vesicles that contribute cell-to-cell communication present various body fluids, such as blood or urine....
Background The individual course of CKD may vary, and improved methods for identifying which patients will experience short-term eGFR loss are needed. Assessing urinary Dickkopf-3 (DKK3), a stress-induced tubular epithelia–derived profibrotic glycoprotein, provide information about ongoing tubulointerstitial fibrosis loss. Methods To investigate DKK3’s potential as biomarker (over 12 months), we prospectively assessed DKK3 levels in with various etiologies at baseline annual follow-ups. We...
In patients with type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease, empagliflozin (EMPA) decreased progression of chronic kidney disease (CKD), likely via a reduction in intraglomerular pressure. Due to prevalent comorbidities, such as hypertension albuminuria, often receive other agents that alter intrarenal hemodynamics, including angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs), calcium channel (CCBs) diuretics. Nonsteroidal...
Abstract Background Risk of kidney function decline in immunoglobulin A (IgA) nephropathy (IgAN) is significant and may not be predicted by available clinical histological tools. To serve this unmet need, we aimed at developing a urinary biomarker-based algorithm that predicts rapid disease progression IgAN, thus enabling personalized risk stratification. Methods In multicentre study, urine samples were collected 209 patients with biopsy-proven IgAN. Progression was defined tertiles the...
Chronic kidney disease (CKD) is a global health burden, yet it still underrepresented within public agendas in many countries. Studies focusing on the natural history of CKD are challenging to design and conduct, because long time-course progression, wide variation etiologies, large amount clinical variability among individuals with CKD. With difference health-related behaviors, healthcare delivery, genetics, environmental exposures, this greater across countries than one locale may not be...
Large clinical trials demonstrated that SGLT2 inhibitors (SGLT2i) slow the progression of kidney function decline in type 2 diabetes. Because underlying molecular mechanisms are largely unknown, we studied effects SGLT2i on gene expression two human proximal tubular (PT) cell lines under normoglycemic conditions, utilizing SGLT2i, namely empagliflocin and canagliflocin. Genome-wide analysis did not reveal substantial differences between these SGLT2i. Microarray hybridization identified 94...
OBJECTIVE Chronic kidney disease (CKD) in diabetes has a complex molecular and likely multifaceted pathophysiology. We aimed to validate panel of biomarkers identified using systems biology approach predict the individual decline estimated glomerular filtration rate (eGFR) large group patients with type 2 CKD at various stages. RESEARCH DESIGN AND METHODS used publicly available “omics” data develop process model representative parsimonious set nine biomarkers: chitinase 3-like protein 1,...
OBJECTIVE The decline of estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes is variable, and early interventions would likely be cost-effective. We elucidated the contribution 17 plasma biomarkers to prediction eGFR loss on top clinical risk factors. RESEARCH DESIGN AND METHODS studied participants PROVALID (PROspective cohort study mellitus for VALIDation biomarkers), a prospective multinational follow-up more than 24 months (n = 2,560; baseline median eGFR, 84...
Importance Type 2 diabetes increases the risk of progressive diabetic kidney disease, but reliable prediction tools that can be used in clinical practice and aid patients’ understanding disease progression are currently lacking. Objective To develop externally validate a model to predict future trajectories estimated glomerular filtration rate (eGFR) adults with type chronic using data from 3 European multinational cohorts. Design, Setting, Participants This prognostic study baseline...
(1) Background: Kidney and cardiovascular diseases are responsible for a large fraction of population morbidity mortality. Early, targeted, personalized intervention represents the ideal approach to cope with this challenge. Proteomic/peptidomic changes largely onset progression these should hold information about optimal means treatment prevention. (2) Methods: We investigated prediction renal or events using previously defined urinary peptidomic classifiers CKD273, HF2, CAD160 in cohort...
Abstract Aims/hypothesis Non-adherence to medication is a frequent barrier in the treatment of patients with type 2 diabetes mellitus, potentially limiting effectiveness evidence-based treatments. Previous studies have mostly relied on indirect adherence measures analyse outcomes based adherence. The aim this study was use LC-MS/MS urine—a non-invasive, direct and objective measure—to assess non-adherence cardiometabolic drugs its association kidney cardiovascular outcomes. Methods This...
The prevalence of diabetes mellitus type 2 and kidney disease in these patients varies widely between European countries.In addition to store bio-samples the "Prospective cohort study with for validation biomarkers" collects information on history, physical status, laboratory measurements medication 4000 2, being taken care at primary level healthcare 5 countries (Austria, Hungary, Netherlands, Poland Scotland). Next comparing rate loss eGFR countries, a further objective PROVALID is...